Financial Performance - The net profit attributable to shareholders for the first half of 2024 is CNY 2,941,911,373.69, with a proposed cash dividend of CNY 0.80 per 10 shares, totaling CNY 296,281,879.28, which accounts for 10.07% of the net profit[3]. - The company's operating revenue for the first half of the year reached ¥139.41 billion, an increase of 5.14% compared to ¥132.59 billion in the same period last year[13]. - Net profit attributable to shareholders was ¥2.94 billion, reflecting a growth of 12.72% from ¥2.61 billion year-on-year[13]. - The net profit after deducting non-recurring gains and losses was ¥2.71 billion, up 23.00% from ¥2.20 billion in the previous year[13]. - The basic earnings per share increased to ¥0.79, representing an 11.27% rise from ¥0.71 in the previous year[14]. - The company's cash flow from operating activities showed a significant decline of 68.55%, totaling ¥515.30 million compared to ¥1.64 billion in the same period last year[13]. - The company reported a net profit of RMB 2,705,163,523.17 for the first half of 2024, representing a 23% increase compared to the same period last year[145]. - The total comprehensive income for the first half of 2023 was RMB 811,247,163.75, indicating a significant year-over-year change[154]. Revenue Breakdown - The pharmaceutical industry segment reported revenue of RMB 12.73 billion, a year-on-year decline of 13.37%, while the pharmaceutical commerce segment achieved revenue of RMB 126.68 billion, a year-on-year increase of 7.45%[29]. - The company's traditional Chinese medicine segment achieved industrial revenue of 5.192 billion RMB in the first half of 2024[35]. - Non-pharmaceutical business sales reached about 21.8 billion RMB, growing approximately 11.12% year-on-year[42]. Research and Development - The company has maintained a leading position in R&D investment intensity, ranking among the top tier of domestic pharmaceutical companies in total R&D investment[24]. - R&D investment increased to 1.404 billion RMB, up 15.26% year-on-year, accounting for 11.03% of industrial sales[34]. - The company has 64 new drug pipelines in clinical research, including 50 innovative drugs and 14 improved new drugs[34]. - The company is actively advancing its cell therapy industrialization layout, having established strategic cooperation with several medical institutions for the development of innovative cell therapy products[31]. Corporate Governance and Management - The company has implemented a scientific committee management approach to optimize its R&D management system and enhance R&D capabilities[33]. - The company has implemented a stock option incentive plan, with a total of 25,600,000 stock options granted to 210 incentive targets initially[68]. - The company aims to enhance corporate governance and prevent talent loss through the incentive plan[70]. - The company has experienced changes in its board and senior management, with key personnel resigning due to work adjustments[91]. Financial Position - The total assets of the company were RMB 221.34 billion, consistent with the total liabilities and equity, indicating a balanced financial position[150]. - The company's equity attributable to shareholders reached RMB 69.99 billion as of June 30, 2024, compared to RMB 68.52 billion at the end of 2023, marking an increase of about 2.2%[150]. - The total liabilities of Shanghai Pharmaceuticals amounted to RMB 221.34 billion, an increase from RMB 211.97 billion as of December 31, 2023, representing a growth of approximately 4.3%[150]. - The company's retained earnings were reported at RMB 35.25 billion as of December 31, 2023, compared to RMB 33.82 billion at the end of 2022, reflecting an increase of about 4.2%[150]. Market Position and Recognition - The company ranked 411th in the 2024 Fortune Global 500, marking its fifth consecutive year on the list[18]. - The company was ranked 42nd in the 2024 Global Pharmaceutical Companies Top 50 by Pharm Exec and 3rd in the 2023 China Pharmaceutical Industry Top 100 by the Southern Pharmaceutical Economic Research Institute[19]. - The company is the second-largest pharmaceutical commercial enterprise in China, with a comprehensive supply chain network covering 25 provinces and municipalities[20]. Cash Flow and Investments - The net cash flow from operating activities decreased significantly by 68.55% to CNY 515.30 million, down from CNY 1.64 billion[45]. - The company reported investment income of RMB 602.80 million, a significant increase from a loss of RMB 198.99 million in the same period last year[152]. - The total cash and cash equivalents at the end of the period reached CNY 33,803,202,802.46, an increase from CNY 28,688,336,307.72 at the end of June 2023[153]. Shareholder Information - The total number of ordinary shareholders reached 70,011 by the end of the reporting period[125]. - The top shareholder, Shanghai Leicai (Group) Co., Ltd., holds 716,516,039 shares, representing 19.347% of the total shares[126]. - The total number of shares increased from 3,703,301,054 to 3,703,523,491, with an addition of 222,437 shares during the reporting period[124]. Compliance and Regulations - The company strictly adhered to the Corporate Governance Code as per Hong Kong listing rules, except for the gender diversity requirement on the board[97]. - The audit committee has reviewed and approved the accounting treatment methods adopted in the 2024 semi-annual report[100]. - The company has committed to ensuring that any equity incentive policies align with the execution of compensation measures[106]. Environmental and Social Responsibility - The company completed the signing of environmental protection responsibility agreements for 20 subsidiaries in the first quarter of 2024[101]. - A total of 65 energy-saving technical improvement projects are planned for 2024, with 35 projects completed by the end of the reporting period, expected to save costs of RMB 7.09 million[101]. - The company aims to establish an ISO50001 system and actively promote photovoltaic project construction as part of its energy management strategy[101].

Financial Performance - The company's operating revenue for the first half of 2024 reached ¥139.41 billion, an increase of 5.14% compared to ¥132.59 billion in the same period last year[19]. - The net profit attributable to shareholders for the first half of 2024 was ¥2.94 billion, representing a 12.72% increase from ¥2.61 billion in the previous year[19]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥2.71 billion, up 23.00% from ¥2.20 billion year-on-year[19]. - Basic earnings per share increased by 11.27% to CNY 0.79 compared to the same period last year[20]. - Diluted earnings per share also rose by 11.27% to CNY 0.79 year-on-year[20]. - The pharmaceutical industrial segment reported revenue of RMB 12.73 billion, a decline of 13.37%, while the pharmaceutical commercial segment generated revenue of RMB 126.68 billion, an increase of 7.45%[36]. - The net profit attributable to shareholders was RMB 2.94 billion, a year-on-year growth of 12.72%, with the industrial business contributing RMB 1.31 billion and the commercial business contributing RMB 1.79 billion[36]. Cash Flow and Assets - The net cash flow from operating activities decreased significantly by 68.55%, amounting to ¥515.30 million compared to ¥1.64 billion in the same period last year[19]. - The total assets of the company at the end of the reporting period were ¥221.34 billion, reflecting a 4.42% increase from ¥211.97 billion at the end of the previous year[19]. - The net assets attributable to shareholders increased to ¥69.99 billion, a rise of 2.14% from ¥68.52 billion at the end of the previous year[19]. - The company's total assets included 6.21 billion RMB in overseas assets, accounting for 2.81% of total assets[58]. - The company's asset-liability ratio is 62.85%, an increase of 0.74 percentage points compared to the beginning of the period[74]. Research and Development - The company increased R&D investment to RMB 1.40 billion, a year-on-year rise of 15.26%, accounting for 11.03% of industrial sales[41]. - The company has 64 new drug pipelines in clinical research, including 50 innovative drugs, with 3 in Phase II clinical trials in the U.S.[41]. - The CAR-T product B019 has officially started clinical trials, and the company is collaborating with major medical institutions for cell therapy product development[38]. - The company maintains a strong R&D investment intensity, ranking among the top tier of domestic pharmaceutical companies[31]. Dividends and Profit Distribution - The company plans to distribute a cash dividend of ¥0.80 per 10 shares, totaling ¥296.28 million, which accounts for 10.07% of the net profit for the first half of 2024[6]. - The proposed profit distribution plan includes a cash dividend of RMB 0.8 per 10 shares[117]. - A cash dividend of 0.80 CNY per 10 shares (including tax) is proposed, totaling 296,281,879.28 CNY, based on a total share capital of 3,703,523,491 shares as of June 30, 2024[118]. Environmental Compliance - Shanghai Pharmaceutical Group reported a COD discharge concentration of 92.49 mg/L and a total discharge of 14.03 tons, with a regulatory limit of 49.12 tons[129]. - The company achieved a non-methane hydrocarbon emission of 8.31 tons, with a total hydrocarbon emission of 15.71 tons, demonstrating adherence to air quality regulations[132]. - The company has implemented new strategies to expand its market presence, focusing on sustainable practices and compliance with environmental regulations[132]. - The company is committed to maintaining compliance with national and local environmental standards, ensuring sustainable operations moving forward[132]. Employee Management and Training - As of June 30, 2024, Shanghai Pharmaceuticals employed 49,234 people, including 1,674 in R&D[79]. - During the reporting period, a total of 4,323 employees participated in 15 training sessions, enhancing their professional knowledge and leadership skills[80]. - The company has established a differentiated compensation system for various roles, linking employee income growth to company performance[79]. - The training programs included a new cadre training class and various functional training sessions, reflecting the company's commitment to talent development[80]. Related Party Transactions - The total amount of related party transactions for the company reached CNY 38,442.76 million, accounting for 100% of similar transactions[171]. - The company reported a related party procurement amount of CNY 29,690.67 million, also representing 100% of similar transactions[171]. - The company has a significant reliance on related party transactions, with all reported transactions being at market prices[171]. Corporate Governance - The company strictly adhered to the corporate governance code as per Hong Kong listing rules, except for the gender diversity requirement on the board[122]. - The audit committee has reviewed and approved the accounting treatment methods adopted in the 2024 half-year report[126]. - The company has committed to ensuring the implementation of profit distribution policies to safeguard investor returns[165]. Future Plans and Strategies - The company plans to maintain the distribution amount per share unchanged, adjusting the total distribution amount based on any changes in total share capital before the implementation date[119]. - The company intends to continue investment mergers and acquisitions, overseas business expansion, and digital transformation initiatives[112]. - The company plans to enhance operational efficiency and quality, focusing on R&D innovation and product planning in the industrial sector[112].

Investment Rating - The report initiates coverage with an "Outperform" rating for Shanghai Pharmaceuticals [4][66]. Core Views - Shanghai Pharmaceuticals is a leading pharmaceutical distributor in China, with strong capabilities in both pharmaceutical distribution and manufacturing. The company achieved sales of RMB 260.3 billion in 2023, representing a year-on-year growth of 12.2% [63][64]. - The pharmaceutical distribution segment is expected to benefit from innovative services and increasing industry concentration, with a projected revenue CAGR of 9.0%-13.7% for leading companies, significantly outpacing the industry average of 6.6% [64][66]. - The pharmaceutical manufacturing segment is anticipated to experience growth driven by traditional Chinese medicine (TCM) rebranding and innovative drugs, with a stable cash flow from generic drugs [65][66]. Summary by Sections 1. Chinese Pharmaceutical Distribution Market - The market size reached RMB 27,516 billion in 2022, with a CAGR of 6.6% from 2017 to 2022. The market is characterized by strong consumer demand and a trend towards consolidation among leading companies [7][8]. - The concentration ratio of the top four companies in the market increased from 37.6% in 2017 to 45.5% in 2022, indicating a strong trend of "the rich getting richer" [11][12]. 2. Shanghai Pharmaceuticals Overview - Shanghai Pharmaceuticals operates in two main segments: pharmaceutical distribution and manufacturing. In 2023, the distribution revenue was RMB 233.8 billion, accounting for 89.8% of total revenue [18][20]. - The company has a robust distribution network covering over 31 provinces and municipalities in China, serving more than 32,000 medical institutions [20]. 3. Pharmaceutical Distribution - The distribution segment is expected to maintain high growth due to innovative services, including a significant partnership with Sanofi worth over RMB 5 billion [21][64]. - The company aims to enhance its market share through both organic growth and acquisitions, leveraging its strong logistics network [24][28]. 4. Pharmaceutical Manufacturing - The manufacturing segment is set to benefit from the launch of innovative drugs, with three innovative drugs already on the market and 68 projects in clinical stages as of 2023 [65][66]. - The TCM segment is implementing a "Big Brand + Big Product" strategy, which is expected to drive revenue growth through rebranding and multi-channel sales [37][65]. 5. Financial Forecast and Valuation - Revenue projections for FY24-26 are RMB 284.8 billion, RMB 311.6 billion, and RMB 340.4 billion, respectively, indicating a three-year CAGR of 9.4% [66]. - The target price for the stock is set at HKD 14.54, based on a DCF model with a WACC of 6.2% and a perpetual growth rate of 3% [66].

Investment Rating - Initiation coverage with an "Outperform" rating and a target price of HKD 14.54 [4] Core Investment Thesis - Shanghai Pharmaceuticals (SH Pharma) is a leading pharmaceutical distributor in China, with dual engines of pharmaceutical distribution and drug manufacturing [2] - The company achieved RMB 260.3 billion in revenue in 2023, a 12.2% YoY growth, with distribution and industrial revenues of RMB 233.8 billion and RMB 26.3 billion respectively [2] - The pharmaceutical distribution business is expected to benefit from innovative services in the short term and industry consolidation in the long term, with the top 4 players holding a 45.5% market share in 2022 [2] - The pharmaceutical manufacturing business is entering a harvest period, driven by traditional Chinese medicine (TCM) brand revitalization and innovative drug pipelines [3] Pharmaceutical Distribution Business - Short-term growth is driven by innovative services, including a RMB 5 billion+ collaboration with Sanofi and comprehensive lifecycle management services for innovative drugs [2] - Long-term growth is supported by market share gains through organic growth and M&A, with the top 4 players' market share increasing from 37.6% in 2017 to 45.5% in 2022 [2] - The CSO business is expected to see explosive growth in 2024, with Q1 2024 revenue surging 128% YoY to RMB 1.7 billion [24] - The company has a strong logistics network covering 31 provinces and serves over 32,000 medical institutions [23] Pharmaceutical Manufacturing Business - The TCM segment is a key growth driver, with a "big brand + big product" strategy driving a 10.3% YoY revenue growth to RMB 9.82 billion in 2023 [43] - The innovative drug pipeline includes 68 clinical projects, with 3 drugs already launched and 3 more expected to be approved by 2025 [39] - The generic drug segment is expected to face short-term pressure in 2024 but will provide stable cash flow from 2025 onwards [46] Financial Performance and Valuation - Revenue is expected to grow at a 9.4% CAGR from FY24 to FY26, reaching RMB 340.4 billion in FY26 [4] - Net profit attributable to shareholders is forecasted to be RMB 5.17 billion, RMB 5.67 billion, and RMB 6.28 billion in FY24-26 respectively [4] - The current valuation implies a FY24/FY25 P/E of 7.7x/7.0x [4] Industry Overview - China's pharmaceutical distribution market reached RMB 27.5 trillion in 2022, with a 6.6% CAGR from 2017 to 2022 [6] - The market is characterized by increasing concentration, with the top 4 players' market share rising from 37.6% in 2017 to 45.5% in 2022 [12] - The industry is expected to continue its steady growth, driven by China's aging population and increasing healthcare expenditure [10]

Financial Performance - The company achieved operating revenue of RMB 70.15 billion in Q1 2024, representing a year-on-year growth of 5.93%[9] - Net profit attributable to shareholders was RMB 1.54 billion, an increase of 1.62% compared to the same period last year[9] - Total operating revenue for Q1 2024 reached ¥70.15 billion, a 5.5% increase from ¥66.23 billion in Q1 2023[33] - Net profit for Q1 2024 was ¥1.87 billion, a decrease of 4.5% compared to ¥1.95 billion in Q1 2023[34] - The company reported a total comprehensive income of ¥1.87 billion for Q1 2024, compared to ¥1.92 billion in Q1 2023[34] Research and Development - Research and development investment reached RMB 715 million, up 30.78% year-on-year, with R&D expenses amounting to RMB 501 million[9] - The company introduced two new drug projects during the reporting period, including I025-A for colorectal cancer and HQ-0124 for schizophrenia[11] - Research and development expenses for Q1 2024 were ¥123.48 million, slightly down from ¥124.55 million in Q1 2023, reflecting a decrease of 0.86%[42] Sales and Segments - The pharmaceutical industrial segment reported sales of RMB 6.94 billion, a decrease of 10.98% year-on-year, while the pharmaceutical commercial segment saw sales of RMB 63.21 billion, an increase of 8.19%[9] - The company’s commercial innovation business experienced a sales increase of approximately 33% in Q1 2024, successfully introducing four new imported products[14] - The CSO contract promotion business achieved sales of approximately RMB 1.7 billion, reflecting a year-on-year growth of about 128%[14] Assets and Liabilities - The company’s total assets at the end of the reporting period were RMB 217.42 billion, a 2.57% increase from the end of the previous year[17] - The total number of issued A-shares is 2,784,228,350, and H-shares are 919,072,704, totaling 3,703,301,054 shares[23] - Total liabilities as of March 31, 2024, were ¥135.33 billion, compared to ¥131.65 billion at the end of 2023, indicating an increase of approximately 2.0%[30] - The total equity attributable to shareholders increased to ¥70.06 billion from ¥68.52 billion, a rise of about 2.2%[30] Cash Flow - Cash flow from operating activities increased by 108.65% due to higher cash outflows for payments[19] - Cash flow from operating activities for Q1 2024 showed a net outflow of ¥5.47 billion, worsening from a net outflow of ¥2.62 billion in Q1 2023[37] - Cash inflow from operating activities totaled $271.4 million in Q1 2024, compared to $75.2 million in Q1 2023, indicating a year-over-year increase of 261%[45] Shareholder Information - The total number of common shareholders at the end of the reporting period was 82,305[22] - The largest shareholder, Shanghai Pharmaceutical Group, holds 716,516,039 shares, accounting for 48% of total shares[22] Other Financial Metrics - The company reported a fair value change gain of ¥31.35 million in Q1 2024, down from ¥79.29 million in Q1 2023, reflecting a decrease of about 60.54%[42] - The company received $10.05 billion from investment recoveries in Q1 2024, up from $9.23 billion in Q1 2023[45] - The company paid $3.3 billion in debt repayments during Q1 2024, compared to $7.2 billion in Q1 2023[46]

（於中華人民共和國註冊成立的股份有限公司） （股份代碼：02607） 2024年第一季度報告 本公告乃根據證券及期貨條例（香港法例第571章）第XIVA部及香港聯合交易所有限公司 證券上市規則第13.09條而發表。 以下為上海醫藥集團股份有限公司2024年第一季度報告，其所載財務報告根據中國企業 會計準則編製，並且未經審計。 承董事會命 上海醫藥集團股份有限公司 楊秋華 董事長 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容 而產生或因依賴該等內容而引致的任何損失承擔任何責任。 上海醫藥集團股份有限公司 Shanghai Pharmaceuticals Holding Co., Ltd. * 中國上海，二零二四年四月二十六日 於本公告日期，本公司的執行董事為楊秋華先生、沈波先生、李永忠先生及董明先生； 非執行董事為陳發樹先生；以及獨立非執行董事為顧朝陽先生、霍文遜先生及王忠先生。 * 僅供識別 - 1 - 本公司董事會及全體董事保證本公告內容不存在任何虛假記載、誤導性陳述或者重大遺 漏，並對其內容的真實 ...

(於中華人民共和國註冊成立的股份有限公司) (H股股份代號：02607) (A股股份代號：601607) 上海醫藥集團股份有限公司 年度報告 2023 * 僅供識別 www.sphchina.com 上海醫藥集團股份有限公司 年年度報告 2023 上海醫藥集團股份有限公司 我們的願景 成為受人尊敬、擁有行業美譽度的領先品牌藥製造商 和健康領域服務商 我們的使命 持之以恆，致力於提升民眾的健康生活品質 我們的核心價值觀 創新、誠信、合作、包容、責任 | 目錄 | | | | --- | --- | --- | | 第一節 | 釋義 | 2 | | 第二節 | 企業資料 | 7 | | 第三節 | 財務摘要 | 9 | | 第四節 | 致股東函 | 10 | | 第五節 | 管理層討論與分析 | 13 | | 第六節 | 董事會報告 | 45 | | 第七節 | 董事、監事及高級管理層情況 | 74 | | 第八節 | 企業管治報告 | 86 | | 第九節 | 財務報表及審計報告 | 97 | 在本報告書中，除非文義另有所指，下列詞語具有如下含義： 常用詞語釋義 | 「本集團」、「集團」、 | 指 | 上海醫藥 ...

Investment Rating - The report maintains a "Buy" rating for Shanghai Pharmaceuticals-A with a target price of RMB 22.37, down from the previous target of RMB 23.63, indicating a potential upside of 27% from the current price of RMB 17.62 [1][6][14]. Core Insights - The company experienced steady revenue growth in 2023, achieving revenue of RMB 263 billion, a year-on-year increase of 12%. However, the net profit of RMB 3.768 billion fell short of expectations, declining by 33% year-on-year [1][2]. - The pharmaceutical distribution segment showed strong performance with revenue of RMB 233.76 billion, up 14% year-on-year, while the pharmaceutical manufacturing segment saw a slight decline in revenue [1][2]. - The innovative drug pipeline is entering a harvest phase, with several new drugs in various stages of clinical trials and applications [2][14]. Financial Summary - In 2023, the company reported a net profit of RMB 3.768 billion, down 33% from the previous year, with a corresponding EPS of RMB 1.02, a decrease of 35% [1][8]. - The operating cash flow for 2023 was RMB 5.232 billion, reflecting a 10% increase year-on-year [1][8]. - The report forecasts a compound annual growth rate (CAGR) for revenue and net profit of 11% and 19%, respectively, from 2023 to 2026 [1][2]. Segment Performance - The pharmaceutical distribution segment generated revenue of RMB 233.76 billion, with a gross margin of 6.3%, down 0.27 percentage points year-on-year [1][9]. - The pharmaceutical manufacturing segment reported revenue of RMB 26.26 billion, a decrease of 2% year-on-year, with a gross margin of 58.5% [2][9]. - The retail segment achieved revenue of RMB 9.11 billion, up 10% year-on-year, but with a declining gross margin of 12.0% [9]. Earnings Forecast Adjustments - Due to lower-than-expected performance in 2023, the report has revised down the earnings forecasts for 2024 and 2025, with EPS estimates adjusted to RMB 1.56 and RMB 1.66, representing decreases of 18% and 19% respectively [3][11][13].

Financial Performance - Shanghai Pharmaceuticals reported a revenue of RMB 100 billion for the fiscal year 2023, representing a year-on-year growth of 15%[3]. - The company achieved a net profit of RMB 8 billion, which is an increase of 10% compared to the previous year[3]. - In 2023, Shanghai Pharmaceuticals reported a revenue of RMB 260,295,089 thousand, representing a year-on-year increase of 12.2% from RMB 231,981,300 thousand in 2022[23]. - The company's profit before tax for 2023 was RMB 7,054,297 thousand, a decrease of 20% compared to RMB 8,808,353 thousand in 2022[23]. - The net profit attributable to the owners of the company for 2023 was RMB 3,768,000 thousand, a decline from RMB 5,617,152 thousand in 2022, representing a decrease of 32.9%[23]. - The gross margin for the year was reported at 40%, maintaining stability compared to the previous year[3]. - The company reported a significant increase in other income, which rose by 101.43% to ¥793.16 million, primarily due to increased government subsidies[95]. - The company's operating revenue for the reporting period reached ¥260.30 billion, an increase of 12.21% compared to ¥231.98 billion in the same period last year[95]. - Operating costs rose to ¥228.97 billion, reflecting a 13.63% increase from ¥201.49 billion, driven by higher sales revenue[95]. Market Expansion and Product Development - Shanghai Pharmaceuticals plans to launch three new products in 2024, targeting a market expansion of 25% in the healthcare sector[3]. - The company aims to expand its market presence in Southeast Asia, with a projected growth rate of 30% in that region[3]. - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of RMB 2 billion allocated for potential mergers[3]. - The company has 68 new drug pipelines in various stages, including 55 innovative drugs and 13 modified new drugs, with 3 innovative drugs submitted for pre-NDA or market application[40]. - The company has 16 ongoing projects in its rare disease platform, focusing on innovative drugs and urgently needed medications[75]. - The company is actively developing I001 for inflammatory bowel disease and diabetic nephropathy, with ongoing patient recruitment[47]. - The company has completed the enrollment for Phase II clinical trials of B013, a new drug for triple-negative breast cancer, with good safety results reported[51]. - The company has 6 projects in Phase III clinical trials, including BCD-100 for cervical cancer and non-small cell lung cancer[42]. Research and Development - The company has invested RMB 1.5 billion in R&D for new technologies, focusing on innovative drug development[3]. - Research and development investment totaled RMB 2.602 billion, with R&D expenses of RMB 2.204 billion, a year-on-year increase of 4.35%[37]. - The total R&D investment for the period amounted to RMB 260,226,000, representing 9.91% of operating revenue[106]. - The company aims to enhance its R&D capabilities by building high-quality teams and establishing open R&D platforms in collaboration with universities and research institutions[132]. - The company is increasing R&D investment and optimizing innovation resource allocation to enhance its competitive edge in innovative drug development[135]. Corporate Social Responsibility and Governance - The company emphasized its commitment to corporate social responsibility, aiming to improve public health quality through various initiatives[3]. - The company’s ESG efforts have been recognized with an AA rating from MSCI and Wind, placing it among the leading peers in the industry[73]. - The company aims to enhance corporate governance and retain talent through the stock option incentive plan, aligning the interests of management with the long-term development of the company[173]. Strategic Partnerships and Collaborations - The company established strategic partnerships with Shanghai Jiao Tong University and China Pharmaceutical University to enhance its innovation capabilities in drug research[27]. - The company has formed a strategic partnership with Sanofi for nationwide multi-channel cooperation, showcasing its strength as China's largest drug and medical device import and export platform[29]. - The company has completed the acquisition of Hunan Runji Pharmaceutical and Zhengda Tianqing's commercial segment, expanding its domestic pharmaceutical distribution network[63]. International Development - The company is actively expanding its international business, with steady growth in international revenue and substantial progress in product registrations[62]. - The company has made significant progress in the Philippines market, with the registration of Rosuvastatin Calcium Tablets and two other products approved for pre-review[64]. - The company plans to accelerate its international development, focusing on generic drugs and innovative drug layouts, while seeking overseas acquisition opportunities[132]. Stock Options and Incentive Plans - The stock option incentive plan approved in December 2019 involved granting 25,600,000 stock options to 210 incentive targets[168]. - The company aims to enhance corporate governance and retain talent through the stock option incentive plan, aligning the interests of management with the long-term development of the company[173]. - The total number of A-share stock options granted under the incentive plan is 24,355,720 shares, which does not exceed 1% of the company's total issued shares as of the report date[177]. - The exercise price for the stock options granted under the incentive plan is set at RMB 18.41 per A-share[183]. - The stock options granted under the incentive plan have a maximum validity period of 60 months from the grant registration date[185].

Recognition and Awards - In 2023, Shanghai Pharmaceuticals was recognized in the "Fortune Global 500" and "Top 50 Global Pharmaceutical Companies," highlighting its comprehensive strength and development foundation[2]. - The company has received 27 national quality awards and 112 provincial and municipal quality awards, reflecting its commitment to quality manufacturing[6]. - The company was recognized in the "Fortune" Global 500 list and ranked among the top 50 global pharmaceutical companies in 2023[32]. - The company has received the "2023 Annual Innovation Award" from the Asia-Pacific Quality Organization[64]. - The company has been recognized as one of the "Top 100 ESG Pioneers" among state-owned enterprises in 2023[64]. Financial Performance - Shanghai Pharmaceuticals reported a revenue of RMB 20 billion for the fiscal year 2023, representing a year-on-year increase of 15%[20]. - The company achieved a net profit of RMB 2.5 billion, which is a 10% increase compared to the previous year[20]. - In 2023, the company's operating revenue reached ¥260.30 billion, an increase of 12.21% compared to ¥231.98 billion in 2022[26]. - The net profit attributable to shareholders was ¥3.77 billion, a decrease of 32.92% from ¥5.62 billion in 2022[26]. - The company reported a significant increase in revenue, achieving a total of 50 billion RMB for the fiscal year 2023, representing a year-over-year growth of 15%[130]. - The company provided a positive outlook for the next quarter, projecting a revenue growth of 10%[133]. Research and Development - Significant progress has been made in the R&D pipeline, with breakthroughs in various clinical stages for biological drugs, chemical drugs, traditional Chinese medicine, and rare disease medications[4]. - The establishment of the Shanghai Pharmaceutical Open Innovation Center and collaboration with academic institutions for drug research signifies its commitment to innovation[4]. - The company has 68 new drug projects in the pipeline, including 55 innovative drugs and 13 improved drugs, with 3 projects submitted for pre-NDA or market application[35]. - The company is actively building an open and diverse innovation ecosystem through increased R&D investment and collaboration with universities and research institutions[34]. - The company has invested significantly in R&D, focusing on innovative drugs, traditional Chinese medicine, and treatments for rare diseases, with 16 projects currently under development in its rare disease platform[57]. Market Expansion and Strategy - Shanghai Pharmaceuticals aims to accelerate international development and enhance its governance and compliance measures to ensure sustainable growth[7]. - The company is expanding its market presence in Southeast Asia, targeting a 30% increase in market share by 2025[20]. - The company plans to strengthen its integrated platform for regional operations and expand its commercial cooperation across multiple fields and channels[7]. - The company is exploring partnerships with international firms to enhance its global reach and innovation capabilities[20]. - The company aims to enhance its digital marketing strategy, aiming for a 40% increase in online sales channels by the end of 2024[130]. Operational Efficiency and Cost Management - Shanghai Pharmaceuticals aims to improve operational efficiency by 15% through digital transformation initiatives[20]. - The company reported a significant decrease in operational costs by 5% due to improved efficiency measures implemented in 2023[130]. - The company aims to reduce operational costs by 8% through efficiency improvements in the supply chain[129]. - The company has implemented strict budget control for sales expenses, ensuring effective management and reduction of costs[105]. - The company has focused on channel cooperation to control expenses while simultaneously pursuing cost-saving measures internally[105]. Corporate Governance and Management - The company has established a comprehensive governance structure, ensuring equal treatment of all shareholders and independent operation of its board and supervisory committee[122]. - The total remuneration for all directors, supervisors, and senior management in 2023 amounted to RMB 43.2417 million[135]. - The company has implemented a comprehensive evaluation mechanism based on core, operational, and constraint indicators for performance assessment and reward[135]. - The board of directors has undergone a re-election process, resulting in changes in several key positions, including the departure of the chairman and vice-chairman[136]. - The company has not faced any penalties from securities regulatory agencies in the past three years[137]. Environmental Responsibility - The company invested 135.28 million yuan in environmental protection during the reporting period[161]. - The company has implemented a comprehensive energy management system, aiming for carbon peak by 2030 and increasing the proportion of green energy year by year[185]. - The company achieved a total reduction of 7,034.3 tons in carbon dioxide equivalent emissions through various carbon reduction measures[185]. - The company has established a wastewater treatment plant with a daily capacity of 1,000 tons, which has been operating normally in 2023[167]. - The company has implemented training and emergency drills throughout 2023, ensuring compliance with environmental safety regulations[176]. Future Outlook - Future guidance estimates a revenue growth of 12% for the next fiscal year, driven by new product launches and market expansion[20]. - The company has set a future revenue guidance of 60 billion RMB for the next fiscal year, indicating an expected growth rate of 20%[130]. - The company plans to enhance its research and development capabilities, focusing on innovative product chains to meet clinical demands[115]. - The company aims to transition to a technology-driven health service provider, enhancing its operational efficiency through digitalization[116]. - The company is considering strategic acquisitions to bolster its market position, with a budget of 100 million allocated for potential deals[129].